The market took two weeks to notice a rare earth resource update, then made up for lost time all at once. A multiple sclerosis drug cleared the FDA for human trials after spending the spring on clinical hold. Bitcoin climbed above $77,000 and pulled a handful of large, US-listed crypto names along with it, though the small-cap end of that trade stayed quiet. None of it moved in a straight line.
Mining & Minerals
Avalon Advanced Materials Surges Amid a Week-Old Rare Earth Resource Update
Avalon Advanced Materials (TSX: AVL, OTCQB: AVLNF) shares climbed roughly 100% to 125% over the trailing week as of August 21, according to multiple market trackers, extending a rally tied back to an August 6 resource update, ten days before this coverage window opened. That release refreshed the resource for the Basal Zone at Avalon’s Nechalacho rare earth project in the Northwest Territories for the first time since 2013: 58.6 million tonnes measured and indicated grading 1.49% total rare earth oxides, plus 130.6 million tonnes inferred at 1.31% TREO, a 42% increase in global contained resource over the 2013 feasibility study.
The market took time to digest that number rather than reacting the same day. Avalon closed up 6.45% on August 18 alone, and appearances at the UBS Global Materials Conference and a Clean Energy Metals investor conference this month kept the story in front of new audiences well after the original release. None of that changes the underlying math: this is an inferred-heavy resource at a project whose 2013 feasibility study was never built, and Avalon has commissioned an updated Preliminary Economic Assessment, expected to complete this fall, that will be the real test of whether the numbers translate into an economic mine.
Biotech & Life Sciences
Quantum BioPharma Keeps Trading Actively Weeks After Its MS Drug Cleared the FDA
Quantum BioPharma (Nasdaq: QNTM, CSE: QNTM) received FDA clearance on August 10 to advance its multiple sclerosis drug candidate, Lucid-MS, into a randomized, placebo-controlled Phase 2 trial, six days before this coverage window opened. The clearance followed a rockier path than the headline suggests: the FDA placed the same IND application on clinical hold in May, pending additional information, before lifting it and clearing the program for Phase 2 in August.
Lucid-MS takes a different approach than most existing MS therapies, targeting the enzyme believed to drive myelin breakdown directly rather than suppressing the immune system broadly, and its Phase 1 data showed no safety or tolerability concerns in healthy volunteers. QNTM is a thinly traded, low-float stock, and some coverage of the company circulating online is explicitly paid promotional content commissioned through third-party IR firms; this article draws only from the company’s own SEC filings and GlobeNewswire releases, not from that promotional coverage.
Green Energy & Cleantech
Standard Uranium Highlights a Fertile Basement System at Its Corvo Project
Standard Uranium (TSXV: STND, OTCQB: STTDF) released additional geological and geochemical interpretation from its winter 2026 drill program at the Corvo Uranium Project near Wollaston Lake, Saskatchewan, on August 20. The company said the results point to a widespread, basement-hosted uranium system across the property, its first drill campaign at Corvo.
This is a system-scale interpretation, not a resource estimate or a standalone high-grade intercept; the company is still working out where within that system future drilling should target. Standard Uranium has been active in the news this month, including a $3 million strategic investment from an undisclosed Southeast Asian energy conglomerate reported in a prior coverage window, so this release reads as incremental technical progress on one property within a larger portfolio rather than a standalone catalyst.
Tech & Innovation: What Moved the Sector This Week
No small or micro-cap TSX or CSE technology company had a standout story this week. The broader AI trade dominated headlines instead: South Korea’s Kospi entered a technical bull market on an AI-driven rebound, gaining over 4% in a single session, and large US semiconductor and AI infrastructure names like Lumentum and CoreWeave posted double-digit single-day gains on strong earnings.
None of that activity concentrated in small or micro-cap Canadian tech names this week; the sector’s Canadian public news flow leaned toward routine corporate items, including at least one company signing a new investor-relations agreement, rather than product or commercial catalysts. Worth watching for small-cap tech investors: whether large-cap AI infrastructure spending eventually filters down into orders for smaller suppliers, something that hasn’t shown up in this week’s news yet.
Crypto & Fintech: What Moved the Sector This Week
Bitcoin traded above $77,000 this week, and crypto-linked equities had one of their best weeks in months after the Trump administration pushed lawmakers to advance the Clarity Act, a digital asset market structure bill. Strategy gained 29%, Coinbase 25%, Circle Internet 22%, and Mara Holdings 21% over the week, each stock’s best weekly performance in months.
All of that activity concentrated in large-cap, US-listed names. No small or micro-cap crypto or fintech company on the TSX or CSE had a comparable story this week; the sector’s Canadian small-cap listings stayed quiet by comparison, a gap worth watching if the rally continues and starts pulling smaller names along with it.
What to Watch Next
Avalon has commissioned an updated Preliminary Economic Assessment for Nechalacho, expected to complete this fall. That study, not the resource update alone, will be the next real test of whether the project’s economics can support development.
The company has started site selection for its Phase 2 trial and plans to begin patient enrollment and dosing as soon as possible. No firm trial start date has been disclosed yet.
The company is still defining specific drill targets within the broader system it identified this week. A follow-up drill program, not yet scheduled, would be the next concrete step.
Not yet visible in this week’s news flow. Watch for order announcements or contract wins from smaller suppliers tied to the ongoing data center and AI infrastructure buildout.
Not yet; this week’s gains concentrated entirely in large-cap US names. Watch whether smaller TSX or CSE-listed crypto and fintech companies see comparable trading activity if the rally continues.
Sources
- Inferred tonnes drive rare earth growth in Avalon update, MINING.COM, August 6, 2026
- Avalon Advanced Materials Inc. company news and conference appearances, CNBC, August 2026
- Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial, GlobeNewswire, August 10, 2026
- Quantum BioPharma Provides Corporate Update (clinical hold), GlobeNewswire, June 1, 2026
- Standard Uranium Highlights Uranium Fertile System at the Corvo Uranium Project, Newsfile Corp, August 20, 2026
- Stock market news for Aug. 12, 2026 (Kospi, AI trade), CNBC
- Stock market news for Aug. 21, 2026 (Bitcoin, Clarity Act), CNBC
Editorial Disclosure
The Tech & Innovation and Crypto & Fintech items in this article cover sector-wide activity; no specific company is the subject of coverage in either section. Tickers discussed as company subjects in this article: AVL / AVLNF (Avalon Advanced Materials), QNTM (Quantum BioPharma), and STND / STTDF (Standard Uranium). aktiego.com has received no compensation from any company, IR firm, or third party in connection with this coverage, and no aktiego.com staff member holds a position in any security named above. Press release dates and primary sources were verified against company IR pages, GlobeNewswire, SEC EDGAR, and Newsfile Corp. Avalon Advanced Materials’ price action this week stems from an August 6 resource update, ten days outside this coverage window. Quantum BioPharma’s FDA clearance is dated August 10, six days outside this coverage window. Some third-party coverage of Quantum BioPharma circulating online is explicitly paid promotional content. Standard Uranium has appeared in prior aktiego.com coverage for a separate project and news item within its portfolio. All companies named as subjects are under $500 million USD in market capitalization as of the dates referenced above. Avalon’s updated resource is inferred-heavy relative to its 2013 feasibility study baseline and has not yet been incorporated into a completed economic study; a new Preliminary Economic Assessment is in progress. Quantum BioPharma’s Lucid-MS program remains in early-stage clinical development with no efficacy data in MS patients yet, and its IND application was previously placed on an FDA clinical hold earlier this year. Standard Uranium’s Corvo results are a geological system-scale interpretation, not a resource estimate. These are speculative investments carrying significant risk including potential total loss of capital. Digital assets are highly volatile. Coverage on aktiego.com is provided for informational and educational purposes only, aktiego.com is not a registered investment advisor, and nothing in this article constitutes financial, investment, or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. For more information please see our full DISCLAIMER.
